Monthly News Roundup - August 2016

FDA Approves Erelzi: Sandoz ’s Biosimilar For Enbrel A third U.S. biosimilar has been FDA-approved; this time it’s Erelzi (etanercept-szzs), a biosimilar to Amgen’s tumor necrosis factor (TNF) blocker Enbrel. Sandoz’s Erelzi is the first...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Enbrel | Pharmaceuticals